» Articles » PMID: 15249675

PD-L1-deficient Mice Show That PD-L1 on T Cells, Antigen-presenting Cells, and Host Tissues Negatively Regulates T Cells

Overview
Specialty Science
Date 2004 Jul 14
PMID 15249675
Citations 336
Authors
Affiliations
Soon will be listed here.
Abstract

Both positive and negative regulatory roles have been suggested for the B7 family member PD-L1(B7-H1). PD-L1 is expressed on antigen-presenting cells (APCs), activated T cells, and a variety of tissues, but the functional significance of PD-L1 on each cell type is not yet clear. To dissect the functions of PD-L1 in vivo, we generated PD-L1-deficient (PD-L1(-/-)) mice. CD4(+) and CD8(+) T cell responses were markedly enhanced in PD-L1(-/-) mice compared with wild-type mice in vitro and in vivo. PD-L1(-/-) dendritic cells stimulated greater wild-type CD4(+) T cell responses than wild-type dendritic cells, and PD-L1(-/-) CD4(+) T cells produced more cytokines than wild-type CD4(+) T cells in vitro, demonstrating an inhibitory role for PD-L1 on APCs and T cells. In vivo CD8(+) T cell responses also were significantly enhanced, indicating that PD-L1 has a role in limiting the expansion or survival of CD8(+) T cells. Studies using the myelin oligodendrocyte model of experimental autoimmune encephalomyelitis showed that PD-L1 on T cells and in host tissues limits responses of self-reactive CD4(+) T cells in vivo. PD-L1 deficiency converted the 129S4/SvJae strain from a resistant to experimental autoimmune encephalomyelitis-susceptible strain. Transfer of encephalitogenic T cells from wild-type mice into PD-L1(-/-) recipients led to exacerbated disease. Disease was even more severe in PD-L1(-/-) recipients of PD-L1(-/-) T cells. These results demonstrate that PD-L1 on T cells, APCs, and host tissue inhibits naïve and effector T cell responses and plays a critical role in T cell tolerance.

Citing Articles

Suppression of MCP-1, IFN-γ and IL-6 production of HNSCC by pembrolizumab added to docetaxel and cisplatin (TP) exceeding those of TP alone is linked to improved survival.

Wellhausen J, Rohl L, Berszin M, Krucken I, Zebralla V, Pirlich M Front Immunol. 2025; 15:1473897.

PMID: 39882242 PMC: 11774711. DOI: 10.3389/fimmu.2024.1473897.


Helminth extracellular vesicles co-opt host monocytes to drive T cell anergy.

Borup A, Sharifpour M, Rossen L, Whitehead B, Boysen A, Olesen R J Extracell Vesicles. 2025; 14(1):e70027.

PMID: 39815783 PMC: 11735955. DOI: 10.1002/jev2.70027.


Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence.

Eshaq A, Flanagan T, Ba Abbad A, Makarem Z, Bokir M, Alasheq A Int J Mol Sci. 2025; 26(1.

PMID: 39795946 PMC: 11719825. DOI: 10.3390/ijms26010088.


PD-L1 Lymphocytes Are Associated with CD4, Foxp3CD4, IL17CD4 T Cells and Subtypes of Macrophages in Resected Early-Stage Non-Small Cell Lung Cancer.

Gureviciene G, Matulione J, Poskiene L, Miliauskas S, Zemaitis M Int J Mol Sci. 2024; 25(19).

PMID: 39409156 PMC: 11477418. DOI: 10.3390/ijms251910827.


Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders.

Lasheen N, Allam S, Elgarawany A, Aswa D, Mansour R, Farouk Z J Physiol Sci. 2024; 74(1):46.

PMID: 39313800 PMC: 11421184. DOI: 10.1186/s12576-024-00933-4.


References
1.
Dong H, Zhu G, Tamada K, Chen L . B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999; 5(12):1365-9. DOI: 10.1038/70932. View

2.
Nishimura H, Nose M, Hiai H, Minato N, Honjo T . Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999; 11(2):141-51. DOI: 10.1016/s1074-7613(00)80089-8. View

3.
Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A . Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001; 291(5502):319-22. DOI: 10.1126/science.291.5502.319. View

4.
Latchman Y, Wood C, Chernova T, Chaudhary D, Borde M, Chernova I . PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001; 2(3):261-8. DOI: 10.1038/85330. View

5.
Lechner O, Lauber J, Franzke A, Sarukhan A, von Boehmer H, Buer J . Fingerprints of anergic T cells. Curr Biol. 2001; 11(8):587-95. DOI: 10.1016/s0960-9822(01)00160-9. View